A prospective phase II study: High-dose pemetrexed as second-line chemotherapy in small-cell lung cancer

Lung Cancer

Volumn 63, Issue 1, 2009, Pages 88-93

  Grønberg, Bjørn H ^a,b   Bremnes, Roy M ^c,d   Aasebø, Ulf ^c,d   Brunsvig, Paal ^e   Fløtten, Øystein ^f   Amundsen, Tore ^a,b   von Plessen, Christian ^f,g   Wang, Mari ^h   Sundstrøm, Stein ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^d UNIVERSITY OF TROMSØ   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^g UNIVERSITY OF BERGEN   (Norway)

^h ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Antimetabolites; Cytotoxic agents; Folic acid antagonists; Medical oncology; Relapse

Indexed keywords

CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLIC ACID; IRINOTECAN; NAVELBINE; PEMETREXED; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; BRAIN METASTASIS; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG MEGADOSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; GOUT; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPTICEMIA; THERAPY EFFECT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TINEA VERSICOLOR; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

EID: 57649092721     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.04.003     Document Type: Article

References (27)

1. Sundstrom S., Bremnes R.M., Kaasa S., Aasebo U., Hatlevoll R., Dahle R., et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 20 (2002) 4665-4672
2. Turrisi III A.T., Kim K., Blum R., Sause W.T., Livingston R.B., Komaki R., et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340 (1999) 265-271
3. Hanna N., Bunn Jr. P.A., Langer C., Einhorn L., Guthrie Jr. T., Beck T., et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24 (2006) 2038-2043
4. Pignon J.P., Arriagada R., Ihde D.C., Johnson D.H., Perry M.C., Souhami R.L., et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327 (1992) 1618-1624
5. Ardizzoni A., Hansen H., Dombernowsky P., Gamucci T., Kaplan S., Postmus P., et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 15 (1997) 2090-2096
6. von Pawel J., Schiller J.H., Shepherd F.A., Fields S.Z., Kleisbauer J.P., Chrysson N.G., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17 (1999) 658-667
7. Eckardt J.R., von Pawel J., Pujol J.L., Papai Z., Quoix E., Ardizzoni A., et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 25 (2007) 2086-2092
8. Jassem J., Karnicka-Mlodkowska H., van Pottelsberghe C., van Glabbeke M., Noseda M.A., Ardizzoni A., et al. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur J Cancer 29A (1993) 1720-1722
9. Masters G.A., Declerck L., Blanke C., Sandler A., DeVore R., Miller K., et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol 21 (2003) 1550-1555
10. Kakolyris S., Mavroudis D., Tsavaris N., Souglakos J., Tsiafaki P., Kalbakis K., et al. Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study. Ann Oncol 12 (2001) 193-197
11. O'Brien M.E., Ciuleanu T.E., Tsekov H., Shparyk Y., Cucevia B., Juhasz G., et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24 (2006) 5441-5447
12. Giaccone G., Donadio M., Bonardi G., Testore F., and Calciati A. Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. J Clin Oncol 6 (1988) 1264-1270
13. Sundstrom S., Bremnes R.M., Kaasa S., Aasebo U., and Aamdal S. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen). Lung Cancer 48 (2005) 251-261
14. Rinaldi D.A., Kuhn J.G., Burris H.A., Dorr F.A., Rodriguez G., Eckhardt S.G., et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 44 (1999) 372-380
15. Mita A.C., Sweeney C.J., Baker S.D., Goetz A., Hammond L.A., Patnaik A., et al. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 24 (2006) 552-562
16. Cripps C., Burnell M., Jolivet J., Batist G., Lofters W., Dancey J., et al. Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study. Ann Oncol 10 (1999) 1175-1179
17. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003) 2636-2644
18. Nakagawa K., Kudoh S., Matsui K., Negoro S., Yamamoto N., Latz J.E., et al. A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. Br J Cancer 95 (2006) 677-682
19. Takimoto C.H., Hammond-Thelin L.A., Latz J.E., Forero L., Beeram M., Forouzesh B., et al. Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. Clin Cancer Res 13 (2007) 2675-2683
20. Chan D.C.C.V., Zhang Z., Helfrich B., Hirsch F.R., Ma D., and Bunn P.A. Studies of pemetrexed and gemcitabine, alone and in combinations, in human lung cancer models. J Clin Oncol 24 (2006) 17114
21. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589-1597
22. Hanna N., Fossella S.F., Pereira F.V., De Marinis J.R., von Pawel F., Gatzemeier J., et al. Pemetrexed in patients (pts) with relapsed small cell lung cancer (SCLC): A phase II study from the Hoosier Oncology Group. J Clin Oncol 24 (2004) 7063
23. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10 (1989) 1-10
24. Raju R.N.N.M., Smith D.A., Richards D.A., Asmar L., Cunneen J.L., Chen R., et al. Pemetrexed (P) in relapsed small cell lung cancer (SCLC): preliminary results of a phase II trial. J Clin Oncol 25 (2007) 7716
25. 2 in 588 patients who progressed after platinum-containing chemotherapy. J Clin Oncol 25 (2007) LBA7727
26. 2 in a randomized phase II study for pretreated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Thorac Oncol 2 (2007) S861
27. Llombart-Cussac A., Martin M., Harbeck N., Anghel R.M., Eniu A.E., Verrill M.W., et al. A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer. Clin Cancer Res 13 (2007) 3652-3659